# PHARMACY **BENEFACT**

Number 1155 • January 2024

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

## *Alberta Drug Benefit List (ADBL)* interim update now available online

Please be advised that the **February 1, 2024** updates to the *ADBL* has been posted online at **ab.bluecross.ca/dbl/publications.php**.

Please refer to the **February 1, 2024** updates for complete listings of products available by special authorization, step therapy/special authorization, restricted benefits, added products, least cost alternative price changes, new established interchangeable groupings, products with a price change and discontinued listings.

Please note that the online *interactive Drug Benefit List (iDBL)* at **ab.bluecross.ca/dbl/idbl\_main1.php** is a near real-time application, and as such, contains the most up-to-date information.

### Removal of temporary benefits from the ADBL

Due to the shortage of Apo-Prednisone 5 mg Tablet (DIN 00312770), **Teva-Prednisone 5 mg Tablet (DIN 00021695)** was added as a temporary benefit for the *ADBL*.

Alberta Blue Cross has confirmed that the shortage for Apo-Prednisone 5 mg Tablet (DIN 00312770) has been resolved.

Teva-Prednisone 5 mg Tablet (DIN 00021695) will no longer be considered a temporary benefit for the *ADBL* after February 17, 2024.

Due to the shortages of Apo-Medroxy 2.5 mg Tablet (DIN 02244726), Teva-Medroxyprogesterone 2.5 mg Tablet (DIN 02221284), Apo-Medroxy 5 mg Tablet (DIN 02244727) and Teva-Medroxyprogesterone 5 mg Tablet (DIN 02221292), **Provera 2.5 mg Tablet (DIN 00708917)** and **Provera 5 mg Tablet (DIN 00030937)** were added as temporary benefits for the *ADBL*.

Alberta Blue Cross has confirmed that the shortages for Apo-Medroxy 2.5 mg Tablet (DIN 02244726), and Apo-Medroxy 5 mg Tablet (DIN 02244727) have been resolved.

Provera 2.5 mg Tablet (DIN 00708917) and Provera 5 mg Tablet (DIN 00030937) will no longer be considered temporary benefits for the *ADBL* after February 23, 2024.





continued next page



continued from previous page

### Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortage for Sandoz Carbamazepine CR 400 mg Sustained-Release Tablet (DIN 02261847) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 21, 2024**. The following grouping was removed from the Critical Supply Product List **January 22, 2024**:

#### CARBAMAZEPINE

#### 400 MG SUSTAINED-RELEASE TABLET

00002261847	SANDOZ CARBAMAZEPINE CR	SDZ	\$ 0.7689
00000755583	TEGRETOL CR	NOV	\$ 0.9034

Alberta Blue Cross has confirmed that the shortage for Caspofungin 50 mg Injection (DIN 02460947) manufactured by Juno Pharmaceuticals Corp. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 22, 2024**. The following grouping was removed from the Critical Supply Product List **January 23, 2024**:

#### CASPOFUNGIN

# 50 MG / VIAL INJECTION JUN \$ 188.7000 00002244265 CANCIDAS MFC \$ 222.0000

Alberta Blue Cross has confirmed that the shortage for Taro-Phenytoin 25 mg/ml Oral Suspension (DIN 02250896) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 23, 2024**. The following grouping was removed from the Critical Supply Product List **January 24, 2024**:

#### PHENYTOIN

00002250896	TARO-PHENYTOIN	TAR	\$ 0.0480
00000023450	DILANTIN-125	BGP	\$ 0.0620

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)

BLUE CROSS

25 MG / ML ORAL SUSPENSION

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1155 2024/01